Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01423903 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT01423903 is a Phase 1 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 45 participants.
The verdict
NCT01423903, a Phase 1 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether OPB-51602 is safe and tolerable when given daily by mouth to subjects with advanced solid tumors.
Interventions
- DRUG OPB-51602
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01423903
The ClinicalTrials.gov registry entry for NCT01423903 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OPB-51602 is the first listed.
NCT01423903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01423903 about?
NCT01423903 is a clinical study titled "Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer". The purpose of this study is to determine whether OPB-51602 is safe and tolerable when given daily by mouth to subjects with advanced solid tumors.
What is the current status of trial NCT01423903?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2010-02. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01423903?
The interventions under investigation include: OPB-51602 (DRUG).
Who is sponsoring clinical trial NCT01423903?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.